Core Viewpoint - COSCIENS Biopharma Inc. has appointed Anna Biehn as the new Chief Executive Officer, effective May 5, 2025, succeeding Gilles Gagnon, who will remain as a Strategic Advisor and Director [1][3]. Company Overview - COSCIENS Biopharma Inc. is a life science company that develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical, and pharmaceutical products [5][6]. - The company focuses on leveraging proprietary extraction technology to produce active ingredients from renewable plant resources [5]. Leadership Transition - Anna Biehn brings over 25 years of experience in global general management and marketing, previously serving as Chief Financial Officer at NuTek Natural Ingredients [2][3]. - Gilles Gagnon has been with the company since 2008 and has played a key role in its growth and positioning [3]. Strategic Vision - The company aims to establish itself as a global leader in natural-based products for health and wellness, capitalizing on the growing demand for natural ingredients [3][4]. - Biehn expressed confidence in COSCIENS' portfolio and technology, highlighting significant innovation opportunities for both near-term and long-term value [3]. Market Position - COSCIENS is listed on both the Nasdaq Capital Market and the Toronto Stock Exchange under the ticker symbol "CSCI" [6].

Core Viewpoint - COSCIENS Biopharma Inc. has initiated its Phase 2a clinical efficacy study for its avenanthramides product, aimed at managing inflammation-related conditions, following a successful Phase 1 trial that demonstrated a favorable safety profile [1][4][5]. Group 1: Clinical Study Details - The Phase 1-2a clinical trial, named the AvenActive study, began in November 2023 and involved 72 healthy subjects, with no significant adverse events reported [3][8]. - The Phase 2a study will enroll 20 patients with mild to moderate inflammation, testing doses of 480 mg and 960 mg per day [4][5]. - Initial dosing for the Phase 2a study is expected to occur on March 14, 2025, at the Montreal Heart Institute [4][8]. Group 2: Product Information - Avenanthramides are di-phenolic compounds found in oats, known for their antioxidant and anti-inflammatory properties [2]. - The study will assess inflammatory biomarkers in blood, focusing on cytokines, chemokines, and high-sensitivity C-reactive protein [5]. Group 3: Company Strategy and Market Potential - The successful completion of the Phase 1 study is viewed as a critical milestone, positioning the company for potential out-licensing and commercialization opportunities [6]. - The company aims to become a global leader in natural-based health and wellness products, with avenanthramides seen as a transformative product [6][10].

As filed with the Securities and Exchange Commission on May 13, 2024 Registration No. 333-277115 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AETERNA ZENTARIS INC. (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant's name into English) (Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices) K ...

As filed with the Securities and Exchange Commission on April 29, 2024 Registration No. 333-277115 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AETERNA ZENTARIS INC. (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant's name into English) (State or other jurisdiction of incorporation or organization) Canada 2834 Not Applicable (Primary Standard Industria ...

FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AETERNA ZENTARIS INC. As filed with the Securities and Exchange Commission on February 15, 2024 Registration No. 333-___________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant's name into English) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Canada 2 ...